STOCKHOLM, April 30, 2019 /PRNewswire/ --Medivir AB (Nasdaq Stockholm: MVIR) today informs that new data from the phase II program of MIV-711, will be presented during the Osteoarthritis Research Society International (OARSI) world congress, which will take place 2-5 May in Toronto,...
from PR Newswire: https://prn.to/2XQ9obG
No comments:
Post a Comment